Kornimate/medical-research-clean huggingface dataset:
impact of periodontal treatment on nt-probnp levels

Conditions: Periodontitis

Summary: in light of the controversy that are already approved but that however still exists regarding the efficacy and influence the management of periodontitis, the aim of this study was to evaluates, at 6-months follow-up, the post-treatment clinical and serum parameters in patients with periodontitis, treated by either intensive scaling and root planing (srp) treatment versus conventional oral hygiene treatment on serum crp and nt-probnp levels. the null hypothesis to invalidate was that there were no variations, in relation to clinical and serum crp and nt-probnp.

this trial was conducted in accordance with the world medical association's declaration of helsinki of 1975, and reviewed in 2016. the local ethical committee approved the study protocol and each patient was carefully informed about the possible inherent risks of the study and provided their informed written consent. subjects with a diagnosis of periodontitis were enrolled in this clinical trial. the inclusion criteria were: 1) good condition of general health, 2) a minimum of 2 teeth for each quadrant with a pocket depth (pd) ranging from 4-6 mm, 3) no involvement of the furcation, 4) a minimum of a six teeth per quadrant, respectively. the exclusion criteria were: 1) periodontal therapy during the last 12 months, 2) assumption of antibiotics during the last 6 months, 3) pregnancy, 4) any systemic condition which might affect the effects of the study treatment, 5) previous or current radiation or immunosuppressive therapies, 5) use of mouthwash containing antimicrobials during the previous 3 months, 6) no use of hormonal contraceptives, 7) medication by anti-inflammatory and immunosuppressive drugs, 8) previous history of hard-drinking, 9) smoking, 10) class ii and iii tooth mobility. patients randomly undergo to full mouth srp (test group) or oral hygiene treatment (control group)

Eligibility criteria:
inclusion criteria: * good condition of general health * a minimum of 2 teeth for each quadrant with * pocket depth (pd) ranging from 4-6 mm * no involvement of the furcation * a minimum of a six teeth per quadrant, respectively exclusion criteria: * periodontal therapy during the last 12 months * assumption of antibiotics during the last 6 months * pregnancy * any systemic condition which might affect the effects of the study treatment * previous or current radiation or immunosuppressive therapies * use of mouthwash containing antimicrobials during the previous 3 months * no use of hormonal contraceptives * medication by anti-inflammatory and immunosuppressive drugs * previous history of hard drinking * smoking * class ii and iii tooth mobility

Keywords: periodontitis serum markers crp nt-probnp
outcomes of patients with venoarterial extracorporeal membrane oxygenation

Conditions: Cardiogenic Shock; Cardiac Arrest

Summary: venoarterial extracorporeal membrane oxygenation (va ecmo)-also referred to as extracorporeal life support-is a form of temporary mechanical circulatory support and simultaneous extracorporeal gas exchange. the objective of this observational, cohort study is to evaluate the short-term and long-term outcomes of patients with va ecmo.


Eligibility criteria:
inclusion criteria: patients receiving va ecmo for cardiopulmonary support exclusion criteria: refusal of consent

Keywords: extracorporeal life support, extracorporeal membrane oxygenation, cardiogenic shock, cardiac arrest
mobile devices to detect early pneumonitis in stage iii nsclc patients on durvalumab.

Conditions: Unresectable Stage III NSCLC

Summary: a study of whether mobile devices can improve the detection of pulmonary aes (including pneumonitis) in stage iii nsclc patients post-crt, while on durvalumab.

patients undergoing post-crt treatment for lung cancer with consolidation durvalumab can experience pulmonary aes that could become severe if not recognized and treated in time. data collected will be used to evaluate the likelihood of early detection of pulmonary aes in unresectable stage iii nsclc patients on durvalumab. this project seeks to understand if multiparametric mobile technology collecting patient reported outcomes, vital signs, and respiratory function, integrate well into a patients daily life and aid physicians in early detection of pulmonary aes.

Eligibility criteria:
select inclusion criteria: * patient has unresectable stage iii nsclc that has not progressed following concurrent platinum-based chemotherapy and radiation therapy and is eligible to receive durvalumab according to the us fda approved package insert. * patient is able and willing to use the mobile application and connected devices. * patient is able to complete qol assessments. select exclusion criteria: * patient is currently oxygen dependent. * patient has comorbidities that will prevent consistent and reliable measurement assessments with multiparametric mobile technology including severe chronic obstructive pulmonary disorder (copd), severe asthma, congestive heart failure \[chf\], interstitial lung disease \[ild\], and others. * patients on other immunotherapy or systemic immunosuppressants. * patients with active or prior autoimmune disease or history of immunodeficiency. * currently pregnant women.

Keywords: nsclc non-small cell lung cancer durvalumab stage iii stage iiia spirometer spirometry pros mobile applications digital applications stage iiib stage iiic device parametric pneumonitis
insulin cardioplegia for poor left ventricular function

Conditions: Left Ventricular Dysfunction

Summary: the purpose of this investigation is to develop a means to improve the recovery of cardiac metabolism and ventricular function following coronary artery bypass surgery (cabg) in patients with poor preoperative ventricular function (e.g. ejection fraction \<40%).

hypothesis insulin added to blood cardioplegia will improve the results of coronary artery bypass graft by reducing the incidence of low output syndrome (i.e., the requirement for inotropic or balloon pump assistance) in patients with a preoperative ejection fraction \<40%.

Eligibility criteria:
inclusion criteria: * patient has been referred for isolated coronary bypass surgery. * lv grade 3 or 4, lvef \<40% by angio, echo, rna. exclusion criteria: * patient is undergoing reoperative surgery (i.e., has had any previous cardiac surgery) * surgeon has planned another procedure in addition to coronary bypass surgery (e.g., valve repair, replacement, ascending aorta repair or replacement, left ventricular aneurysm resection, repair of congenital defect, carotid surgery, repair of abdominal aortic aneurysm). * patient is scheduled for minimally invasive surgery. * more recent assessment of lv function with lv grade 1 0r 2, lvef\>40%. * 5 or 6 days post mi.

Keywords: myocardial protection myocardial metabolism ventricular function cardiovascular disease cardioplegic additives
pk/pd relationship of caz/avi and fos in the treatment of patients with infections due to cre

Conditions: Gram Negative Infections; Antimicrobial Resistance (AMR)

Summary: a multicenter international prospective observational pharmacological study in adult patients (≥18 years) treated with ceftazidime/avibactam (caz/avi) alone or with caz/avi plus fosfomycin (fos) for infection due to carbapenem-resistant enterobacterales (cre) (kpc and/or oxa-48).

gram-negative infections, particularly those caused by carbapenem-resistant enterobacterales (cre), have a dramatic impact on patient survival. despite the introduction of new drugs in the last years have improved the outcome of patients with cre infections, mortality and relapse rates are still relevant, especially in patients with high-risk source as pneumonia, and those in which the attainment of optimal exposure could be reduced by underlying renal disease. the use of combination regimen in these scenarios has been proposed. however, a standardized approach is still missing. since several in vitro studies have highlighted the synergistic effect of fosfomycin (fos) with different antibiotic classes, including cephalosporins such drug could be an appealing option in combination therapy for the management of cre infections. in particular, the primary aim of the study is to assess the probability of achieving a pre-defined target of efficacy in patients treated with ceftazidime/avibactam (caz/avi) and/or fos according to different modes of drug administration in patients with cre infections. secondary aim is to assess the association between plasma drug concentration of both caz/avi and fos and patient response.

Eligibility criteria:
inclusion criteria: * signature of the informed consent * age ≥ 18 years * adult patients treated for ≥ 48 hours with caz/avi or caz/avi plus fos for a microbiologically documented cre infection exclusion criteria: * polymicrobial/mixed infections with exception of cases with multiple enterobacterales susceptible to study drugs

Keywords: gram negative infection ceftazidime/avibactam fosfomycin pharmacokinetics/pharmacodynamics targets carbapenem-resistant enterobacterales (cre)
switching from octreotide to lanreotide - a look back at patients with neuroendocrine tumors

Conditions: Neuroendocrine Tumors

Summary: the purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.


Eligibility criteria:
inclusion criteria: * males and females age 18 years or older at time of locally advanced or metastatic diagnosis * patients with a confirmed diagnosis of locally advanced or metastatic gastroenteropancreatic neuroendocrine tumour (gep-net) * patients who switched treatment from long acting octreotide lar to lanreotide, where both treatments were received for the treatment of locally advanced or metastatic gep-net. i. treatment with long acting octreotide lar monotherapy for at least 90-days before treatment with lanreotide monotherapy (rescue ssa# use permitted). ii. treatment with lanreotide monotherapy for at least 90-days after treatment with long acting octreotide monotherapy (rescue ssa# use permitted) exclusion criteria: * patients with other malignant disease * patients who participated in a concomitant clinical trial related to treatment of gep-net * patients being treated with a somatostatin analogue (ssa) in combination with other net treatments excluding rescue ssa# * patients who received other primary treatment (e.g., targeted therapy, chemotherapy) for gep-net during the interval between octreotide and lanreotide * patients with net familial genetic syndrome (i.e., men1)
colchicine to quench the inflammatory response after deep vein thrombosis (the conquer-dvt pilot trial)

Conditions: Venous Thromboembolism

Summary: purpose of the pilot trial: to assess the feasibility of a full-scale, double-blind, placebo-controlled, randomized trial assessing whether low-dose colchicine (0.5 mg daily) reduces the risk of post-thrombotic syndrome (pts) in patients with proximal lower extremity deep vein thrombosis (dvt).

eligible and consenting patients will be randomized via a central web-based randomization system (1:1 ratio) to receive one tablet of colchicine 0.5 mg or identical matching placebo daily starting within 7 days of initiation of anticoagulation for acute, symptomatic, proximal lower extremity deep vein thrombosis (dvt) for a treatment course of 180 days (+/- 7 days). study drug will start within 24 hours of randomization. the type, dose, and duration of anticoagulant therapy : unfractionated heparin, low molecular weight heparin (lmwh), fondaparinux, direct oral anticoagulation (doac) or vitamin k agonist (vka) will be left to the discretion of the treating physician or local investigator. the study drug will be continued until the end of the treatment period (180 days +/- 7 days). all patients will be observed until the end of study follow-up (365 days +/- 7 days).

Eligibility criteria:
inclusion criteria: * consenting patients 18 years of age or older with a first, acute, symptomatic proximal (popliteal vein or more proximal) objectively confirmed dvt of the lower extremity will be eligible to participate in the study. exclusion criteria: 1. history of an allergic reaction or significant sensitivity to colchicine. 2. requirement of colchicine for other indications. 3. active or chronic diarrhea, or documented inflammatory bowel disease (i.e., crohn's disease or ulcerative colitis), collagenous colitis or irritable bowel syndrome or existing blood dyscrasias. 4. known or suspected, recent (\<30 days) or active infections (acute or chronic). 5. history of cirrhosis, chronic active hepatitis, or severe liver disease. 6. recent (\<30 days) or chronic use of systemic (oral, intravenous) immunosuppressive drugs (including but not limited to steroids, tumor necrosis factor-alpha blockers, cyclosporine). 7. known active cancer. 8. any of the following as measured within the past 1-3 months or at screening: alanine, or aspartate aminotransferase \>3 times the upper limit of normal, total bilirubin \>2 times the upper limit of normal and a creatinine clearance by cockcroft-gault formula \<30 ml/min. 9. pregnancy, breast feeding or may be considering pregnancy during the study period or women of childbearing potential unwilling to use appropriate contraception during sex; 10. the use of medication with known drug-to-drug interactions (including but not limited to erythromycin or clarithromycin). 11. unable or unwilling to provide consent.

Keywords: proximal lower extremity deep vein thrombosis randomized trial colchicine post thrombotic syndrome inflammation
a study of gt160-246 versus vancomycin in patients with clostridium difficile-associated diarrhea

Conditions: Clostridium Difficile-Associated Diarrhea; Clostridium Enterocolitis; Clostridium Difficile Diarrhea; Antibiotic-associated Colitis; Antibiotic-associated Diarrhea

Summary: approximately 300 patients will be entered into this study taking place throughout the united states, canada and the united kingdom. this study aims to determine if an investigational drug is safe and effective for treating the symptoms of c. difficile-associated diarrhea and lowering the risk of repeat episodes of diarrhea. the investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. all study-related care is provided including doctor visits, physical exams, laboratory tests and study medication. total length of participation is approximately 10 weeks.


Eligibility criteria:
inclusion criteria: * be at least 18 years old. * have active mild to moderate c. difficile- associated diarrhea (cdad). * be able to tolerate oral medication. * not be pregnant or breast-feeding. * sign and date an informed consent form.

Keywords: c. difficile-associated diarrhea cdad clostridium difficile-associated diarrhea clostridium enterocolitis antibiotic-associated diarrhea clostridium difficile colitis infectious diarrhea chronic diarrhea antibiotic-associated colitis
suicide in urban natives: detection and networks to combat events

Conditions: Suicide Prevention

Summary: this study compares the effectiveness of a program to detect and manage suicide risk among american-indian and alaska native (ai/an) youth. half of the participants will receive caring text messages to reduce suicidal thoughts, attempts, and hospitalizations and to increase engagement, social connectedness, and resilience in at-risk youth. the other half will receive usual care that does not include the caring text messages.

the study, "suicide in urban natives: detection and networks to combat events," builds on screening, brief intervention and referral to treatment (sbirt), carried out through the primary care setting, to detect and manage suicide risk. this approach is multilevel, targeting both the healthcare system and the individual, and links screening to existing mobile phone technologies shown to promote resilience and to tap the protective benefits of social connectedness. this collaborative hub will conduct a randomized control trial that compares the effectiveness of enhancing these sbirt programs by sending caring text messages to reduce suicidal ideation, attempts, and hospitalizations, and to increase engagement, social connectedness, and resilience. the investigators' long-term goal is to disseminate and translate the lessons learned into practical policy, organizational changes, and preventive innovations that optimize patient-centered health outcomes and ultimately reduce or eliminate the dramatic and tragic suicide-related health disparities among urban ai/an youth and young adults.

Eligibility criteria:
inclusion criteria: * self-identify as american indian or alaska native; * screen positive for mild, moderate, or severe risk of suicidality (referred by a clinical provider); * have a text-enabled mobile phone; * willing to be contacted by text; * able to participate voluntarily; * speak and read english; * cognitively able to independently provide written informed consent exclusion criteria: * under age 18 * in danger of imminent self-harm; * hospitalized

Keywords: american indian alaska native youth and young adult sbirt
the relationship of platelet counts with sickle cell anemia in the eastern region of saudi arabia

Conditions: Sickle Cell Anaemia; SCD

Summary: this study aims to evaluate the relationship between platelet counts and sickle cell disease in the eastern region of the kingdom of saudi arabia.

introduction: this study aims to evaluate the relationship between platelet counts and sickle cell disease in the eastern region of the kingdom of saudi arabia. purpose: this study aims to assess the prevalence and factors associated with elevated platelet counts in people with sickle cell disease in the eastern region of saudi arabia. methods: this cross-sectional study at majmaah university will analyze prerecorded data frfom the eastern region of saudi arabia to investigate the relationship between platelet counts and sickle cell disease, identifying associated factors and assessing the link . importance: to assess the relationship between platelet counts and disease severity in pationt with scd. aim :to investigate the relationship between platelet counts and scd in the eastern region of the kingdom of saudi arabia.

Eligibility criteria:
inclusion criteria: all the diagnosed patients of sickle cell disease regardless of age and gender. exclusion criteria: patients without having sickle cell disease regardless of age and gender.
comparison of covid-19 and h1n1 influenza pneumonia

Conditions: COVID-19; H1N1 Influenza

Summary: to explore the different clinical and ct features distinguishing covid-19 from h1n1 influenza pneumonia.

covid-19 pneumonia patients showed less proportions of underlying diseases, fever and respiratory symptoms than those of h1n1 pneumonia patients (p\<0.01). white blood cell count, neutrophilic granulocyte percentage, c-reactive protein, procalcitonin, d-dimer and lactate dehydrogenase in h1n1 pneumonia patients were higher than those of covid-19 pneumonia patients (p\<0.05). h1n1 pneumonia were often symmetrically located in the dorsal part of lung inferior lobes, while covid-19 pneumonia were unsually showed a peripheral but non-specific lobe distributions. ground glass opacity was more common in covid-19 pneumonia and consolidation lesions was more common in h1n1 pneumonia (p\<0.01). covid-19 pneumonia lesions showed a relative clear margin compared with h1n1 pneumonia. crazy-paving pattern, thickening vessels, reversed halo sign and early fibrotic leisions were more common in covid-19 pneumonia than h1n1 pneumonia (p\<0.05). pleural effusion in covid-19 pneumonia was significantly less common than h1n1 pneumonia (p\<0.01). compared with h1n1 pneumonia in zhejiang, china, the clinical manifestations of covid-19 pneumonia was more concealed with less underlying diseases and slighter respiratory symptoms. the more common ct manifestations of covid-19 pneumonia included ground glass opacity with a relative clear margin, crazy-paving pattern, thickening vessels, reversed halo sign and early fibrotic leisions, while the less common ct manifestations of covid-19 pneumonia included consolidation and pleural effusion.

Eligibility criteria:
inclusion criteria: * pneumonia exclusion criteria: * no pneumonia

Keywords: covid-19, h1n1, tomography, x-ray computed
intravaginal vibratory stimulus and pelvic floor muscle training

Conditions: Urinary Incontinence

Summary: this is a randomized blinded trial with non-probabilistic sampling for convenience. our goal is to compare pfmt with intravaginal vibratory stimulus versus pfmt alone on the treatment of female urinary incontinence.

this is a randomized blinded trial with non-probabilistic sampling for convenience. our goal is to compare pfmt with intravaginal vibratory stimulus versus pfmt alone on the treatment of female urinary incontinence. women with an indication for conservative treatment of urinary incontinence will be referred to the pelvic floor physiotherapy team by the medical team of the ambulatory of urogynecology and obstetrics of the hospital de clínicas de porto alegre and those who are in compliance with the inclusion criteria proposed for the research will be invited to participate in the study.

Eligibility criteria:
inclusion criteria: * women with urinary incontinence; * know how to perform a voluntary pelvic floor muscle contraction; * have not undergone pelvic floor muscle training in the last 6 months; * understand the instruments used in research. exclusion criteria: * latex allergy; * neurological diseases; * pelvic organ prolapse \> grade 2; * pain during vaginal palpation and / or introduction of the vaginal probe; * vaginal atrophy;
changes in adrenal hormones during adrenal radiofrequency ablation

Conditions: Adrenal Tumors

Summary: the purpose of this study is to evaluate changes in adrenal hormones during adrenal radiofrequency (rf) ablation.

adrenal radiofrequency (rf) ablation has been increasingly used for the treatment of unresectable adrenal tumors. but one of the major complication is a increase in blood pressure. hormonal release during rf ablation is considered the cause of hypertension. but there has been no evidence that adrenal hormones affects changes in blood pressure. in this prospective study, we evaluate the changes in adrenal hormones during rf ablation and clarify the cause of hypertensive crisis.

Eligibility criteria:
inclusion criteria: * unresectable adrenal tumor which will be treated by radiofrequency (rf)ablation * blood pressure is 140mmhg or less before rf ablation * age of 20-years or more * performance status of 0 or 1 * agreement from the patient exclusion criteria: * platelet count of 50,000/mm\^3 or international normalized ratio (inr)\>1.5

Keywords: adrenal gland
registry for upper gastrointestinal bleeding

Conditions: Peptic Ulcer Hemorrhage; Peptic Ulcer, Acute With Hemorrhage

Summary: this project aims to evaluate the data on all patients undergoing endoscopic therapy for upper gastrointestinal bleeding.

this project is being performed to evaluate the outcomes of patients undergoing endoscopic procedures for upper gastrointestinal bleeding at all adventhealth hospitals in central florida. this information will enable quality control of patients undergoing treatment for upper gastrointestinal bleeding across all campuses in the adventhealth system in central florida and hence improve the delivery ot care extended to the investigator's patients.

Eligibility criteria:
inclusion criteria: * patient is 18 years of age or greater * patient is undergoing endoscopic treatment for upper gastrointestinal bleeding exclusion criteria: * under the age of 18 * patient not undergoing endoscopic treatment for upper gastrointestinal bleeding